Gore Launches Clinical Quality Improvement (CQI) Project of New Hernia Repair Device
New research methodology will procure real world feedback from surgeons and patients to improve outcomes with GORE® SYNECOR Biomaterial
Gore Prevails in Heart Device Patent Infringement Suit
W. L. Gore & Associates (Gore) today announced a favorable ruling involving the GORE® HELEX® Septal Occluder.
First Successful Implant of GORE® SYNECOR Biomaterial in a Ventral Hernia Patient
Unique biomaterial for hernia repair implanted for the first time in Gore’s Clinical Quality Improvement project
Global Vascular Thought Leaders Document Shift toward Individualizing Patient Care in Surgical Bypass
Presentations and Discussions from the Surgical Bypass Summit Available at www.surgicalbypass.com
Gore Launches Early Cannulation Capable GORE® ACUSEAL Vascular Graft
Results of early cannulation clinical trial presented at the 2013 VEITHsymposium
Study Confirms GORE® BIO-A® Tissue Reinforcement a Proven Alternative to Biologics in Hernia Repair
Two-year study demonstrates improved patient satisfaction with Gore material
Nominees Announced for 2016 Pioneers in Performance Awards for North America; Online Voting Opens at www.PioneersInPerformance.com
Awards program honors medical specialists advancing therapy and improving patient and clinical performance through active collaboration
Gore Marks 20th Year on 100 Best Companies to Work For® List
Gore has appeared in every edition of the rankings, published annually in Fortune magazine. The company is among just 12 “Great Place to Work Legends” to hold this distinction.
Gore Announces First-in-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR
New delivery system provides controlled and predictable placement of Gore’s highly conformable and time-tested stent graft